Overview

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
Glycine
Ixazomib